{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:28Z","timestamp":1791521428480,"version":"4.3.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Langerhans cell histiocytosis (LCH) involving the female genital region is uncommon and can closely resemble chronic inflammatory, infectious, or neoplastic vulvar diseases. We report a case of a 35-year-old woman with a 6-month history of recurrent painful brownish-red plaques, nodules, erosions, and ulcerations that began in the perianal region and subsequently extended to the vulva. Topical fusidic acid only provided temporary symptomatic relief. Histopathological examination revealed epidermal erosion and crusting, acanthosis, elongated rete ridges, and a dense dermal and subcutaneous infiltrate containing numerous large histiocytes with pale eosinophilic cytoplasm and focal nuclear grooves. Immunohistochemical analysis revealed that the lesional cells exhibited positivity for S100, CD1a, and langerin and negative for HMB45, SOX10, ALK-1A4, and BRAF V600E. Broader molecular testing for MAPK-pathway alterations was not performed, and the lesion was therefore described as BRAF V600E-immunonegative rather than genetically BRAF\/MAPK wild type. The pathological diagnosis was vulvar LCH, with clinically suspected involvement of the perianal region. Positron emission tomography\/computed tomography (PET\/CT) revealed an enlarged cervical lymph node, with no other abnormalities documented; its relationship to LCH could not be determined. Oral thalidomide (50\u2005mg nightly) was subsequently administered while topical Pevisone was continued. Symptomatic improvement, particularly pain relief, was observed after 1 week, and further clinical improvement of the anogenital lesions was documented at 3 months. Because both therapies were used concomitantly, the independent contribution of thalidomide could not be determined. This case underscores the diagnostic challenges associated with anogenital LCH and documents short-term clinical improvement during a low-dose thalidomide-containing regimen without establishing thalidomide monotherapy efficacy. It also highlights the necessity for biopsy, comprehensive systemic evaluation, and ongoing follow-up.<\/jats:p>","DOI":"10.3389\/fmed.2026.1969330","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:27:06Z","timestamp":1791520026000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Extensive vulvar and perianal langerhans cell histiocytosis with clinical improvement during low-dose thalidomide and topical therapy: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Pan","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Mei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.gore.2017.08.005","article-title":"Langerhans cell histiocytosis limited to the female genital tract: a review of literature with three additional cases","volume":"22","author":"Wieland","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejogrb.2012.03.010","article-title":"Management of adult primary vulvar langerhans cell histiocytosis: review of the literature and a case history","volume":"163","author":"El-Safadi","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8483008","DOI":"10.1155\/2022\/8483008","article-title":"Isolated langerhans cell histiocytosis of the vulva in a 28-year-old lady: a report of a case and brief review of the literature","volume":"2022","author":"Sadati","year":"2022","journal-title":"Case Rep Dermatol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.4103\/ijmr.IJMR_648_18","article-title":"Female genital tuberculosis: revisited","volume":"148","author":"Sharma","year":"2018","journal-title":"Indian J Med Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jama.2021.23487","article-title":"Diagnosis and treatment of sexually transmitted infections: a review","volume":"327","author":"Tuddenham","year":"2022","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jdv.16946","article-title":"2020 European guideline on the management of syphilis","volume":"35","author":"Janier","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-021-00614-7","article-title":"Vulvar melanoma: molecular characteristics, diagnosis, surgical management, and medical treatment","volume":"22","author":"Wohlmuth","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/PAS.0b013e31815b212b","article-title":"Immunohistochemical expression of langerin in langerhans cell histiocytosis and non-langerhans cell histiocytic disorders","volume":"32","author":"Lau","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/ajh.26938","article-title":"Molecular and clinicopathologic characterization of pediatric histiocytoses","volume":"98","author":"H\u00e9lias-Rodzewicz","year":"2023","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1078-0432.CCR-24-1802","article-title":"BRAF deletion in adult patients with langerhans cell histiocytosis correlates with multisystem disease and poor outcomes","volume":"31","author":"Lang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.12998\/wjcc.v12.i28.6222","article-title":"Recurrent multisystem langerhans cell histiocytosis involving the female genitalia: a case report","volume":"12","author":"Yuan","year":"2024","journal-title":"World J Clin Cases"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3324\/haematol.2023.283295","article-title":"Dabrafenib and trametinib in langerhans cell histiocytosis and other histiocytic disorders","volume":"109","author":"Cournoyer","year":"2024","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","article-title":"Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric langerhans cell histiocytosis","volume":"7","author":"Whitlock","year":"2023","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem Soc Rev"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1969330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:27:07Z","timestamp":1791520027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1969330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1969330"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1969330","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1969330"}}